Search results
Results From The WOW.Com Content Network
Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, [10] [12] is the S(+) enantiomer of ketamine. [5] [13] It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression.
Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K ...
However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression. Currently, the Food and Drug Administration (FDA) only approves ketamine for use as ...
According to the United States Drug Enforcement Administration (DEA), ketamine is a "dissociative anesthetic that has some hallucinogenic effects" and "can induce a state of sedation, immobility ...
NMDA receptor antagonists induce a state called dissociative anesthesia, marked by catalepsy, amnesia, and analgesia. [1] Ketamine is a favored anesthetic for emergency patients with unknown medical history and in the treatment of burn victims because it depresses breathing and circulation less than other anesthetics.
[4] [5] [6] According to Pender (1972), "the state has been designated as dissociative anesthesia since the patient truly seems disassociated from his environment." [ 7 ] Both Pender (1970) and Johnstone et al. (1959) reported that patients under anaesthesia due to either ketamine or phencyclidine were prone to purposeless movements and had ...
Esketamine, sold under the brand name Spravato and produced by Janssen Pharmaceuticals, was approved by the FDA in March 2019 for the treatment of Treatment-Resistant Depression (TRD) and suicidal ideation. [8] As of 2022, it is the only psychoplastogen approved in the US for the treatment of a neuropsychiatric disorder. [6]
Spravato is made from esketamine, which is derived from ketamine—a Schedule III drug that’s FDA-approved as an anesthetic (and often abused) but has shown promise as an off-label IV treatment ...